☆ 4.8 Article

Host immune responses in aged rhesus macaques against BBV152, an inactivated SARS-CoV-2 vaccine, and cross-neutralization with beta and delta variants

FRONTIERS IN IMMUNOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Biotechnology & Applied Microbiology

Evaluation of immunogenicity post two doses of inactivated SARS-CoV-2 vaccine, Covaxin after six months

Rima R. Sahay et al.

Summary: This study evaluated the immune response of two doses of Covaxin given one month apart in two adult populations (COVID-19 naive-vaccinated individuals and COVID-19 recovered individuals). The study observed a sustained immune response with the presence of antibodies for up to six months after vaccination. The findings highlight the importance of a booster dose after six months of vaccination.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2023)

Add to Collection

Article Multidisciplinary Sciences

Population antibody responses following COVID-19 vaccination in 212,102 individuals

Helen Ward et al.

Summary: Population antibody surveillance is crucial for tracking immune responses to COVID-19 vaccinations. The study found that antibody positivity peaks 4-5 weeks after the first dose of the vaccine and then declines. Age, gender, comorbidities, and infection history affect antibody positivity rates.

NATURE COMMUNICATIONS (2022)

Add to Collection

Letter Infectious Diseases

Elevated neutralization of Omicron with sera of COVID-19 recovered and breakthrough cases vaccinated with Covaxin than two dose naive vaccinees

Pragya D. Yadav et al.

JOURNAL OF INFECTION (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Booster dose of the inactivated COVID-19 vaccine BBV152 (Covaxin) enhances the neutralizing antibody response against Alpha, Beta, Delta and Omicron variants of concern

Gururaj Rao Deshpande et al.

Summary: The neutralizing antibody responses significantly increased after the third dose of BBV152/Covaxin against B.1 (19.11-fold), Delta (16.51-fold), Beta (14.70-fold), and Omicron (18.53-fold) Variants of concern, compared to the two-dose vaccine, providing assurance of a protective immune response in recipients.

JOURNAL OF TRAVEL MEDICINE (2022)

Add to Collection

Article Multidisciplinary Sciences

Protective efficacy of COVAXIN® against Delta and Omicron variants in hamster model

Pragya D. Yadav et al.

Summary: The immunity acquired from natural infection or vaccinations against SARS-CoV-2 weakens over time. COVAXIN(R) showed effective protection against the Delta variant after two or three doses of immunization, as well as reduced lung disease severity against the Omicron variants (BA.1.1 and BA.2) in a Syrian hamster model. The study suggests that administering a booster dose of COVAXIN(R) can enhance vaccine effectiveness against Delta variant infection and provide protection against the BA.1.1 and BA.2 variants.

ISCIENCE (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques

Wei Deng et al.

Summary: Sequential immunization with different types of vaccines can increase neutralizing antibody levels against variants such as Delta and Omicron, providing protection against infection, which could be a potential strategy to counter newly emerging variants.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Three doses of prototypic SARS-CoV-2 inactivated vaccine induce cross-protection against its variants of concern

Tianhong Xie et al.

Summary: This study found that the prototypic SARS-CoV-2 inactivated vaccine provided protection against Alpha, Beta, Delta, and Omicron variants, reducing viral loads and improving lung pathology.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)

Add to Collection

Article Multidisciplinary Sciences

Correlates of protection against SARS-CoV-2 in rhesus macaques

Katherine McMahan et al.

Summary: Adoptive transfer of purified IgG from convalescent macaques protects naive macaques against SARS-CoV-2 infection, and cellular immune responses contribute to protection against rechallenge with SARS-CoV-2. The findings suggest that relatively low antibody titres are sufficient for protection against SARS-CoV-2 in macaques, while higher antibody titres are required for treatment of SARS-CoV-2 infection.

NATURE (2021)

Add to Collection

Article Infectious Diseases

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

Raches Ella et al.

Summary: BBV152 vaccine, consisting of whole-virion inactivated SARS-CoV-2 with Algel and IMDG, showed high neutralizing antibody responses in phase 1 trial and better reactogenicity in phase 2 trial. The 6 mu g with Algel-IMDG formulation has been chosen for phase 3 efficacy trial.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Multidisciplinary Sciences

Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates

Kizzmekia S. Corbett et al.

Summary: The study found that neutralizing antibody responses against several variants of concern gradually declined after vaccination with the mRNA-1273 vaccine for the SARS-CoV-2 virus. However, boosting nonhuman primates with either homologous or heterologous mRNA-1273 vaccines after 6 months resulted in increased neutralizing antibody responses across all variants of concern, which lasted for at least 8 weeks after the boost. After being challenged with the SARS-CoV-2 Beta variant 9 weeks post-boost, viral replication was low to undetectable in bronchoalveolar lavage and significantly reduced in nasal swabs in all boosted animals, indicating the potential necessity for booster vaccinations to maintain immunity and protection.

SCIENCE (2021)

Add to Collection

Article Multidisciplinary Sciences

Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques

Pragya D. Yadav et al.

Summary: This study demonstrates the protective efficacy and immunogenicity of the inactivated SARS-CoV-2 vaccine BBV152 in rhesus macaques, indicating that the vaccine candidate is in clinical development.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Infectious Diseases

COVID-19 case fatality risk by age and gender in a high testing setting in Latin America: Chile, March-August 2020

Eduardo A. Undurraga et al.

Summary: Early severity estimates of COVID-19 are crucial for assessing the impact of the pandemic. In Chile, real-time delay-adjusted case fatality rates show higher impact on male seniors, especially those aged 70 and above. The peak in estimated CFR during the epidemic peak may be due to insufficient laboratory capacity leading to lower reporting rates.

INFECTIOUS DISEASES OF POVERTY (2021)

Add to Collection

Article Multidisciplinary Sciences

Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation

Brunda Ganneru et al.

Summary: The study reports the development and evaluation of a whole virion inactivated COVID-19 vaccine, showing high antigen-binding and neutralizing antibody titers in mice, rats, and rabbits, with excellent safety profiles.

ISCIENCE (2021)

Add to Collection

Editorial Material Public, Environmental & Occupational Health

Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin

Pragya D. Yadav et al.

JOURNAL OF TRAVEL MEDICINE (2021)

Add to Collection

Article Immunology

Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield™®) and BBV-152 (Covaxin™®) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study

Awadhesh Kumar Singh et al.

Summary: A study on Indian healthcare workers found that both Covishield and Covaxin vaccines elicited good immune response after two doses, with significantly higher seropositivity rates and GMT of anti-spike antibody in Covishield recipients compared to Covaxin recipients.

VACCINE (2021)

Add to Collection

Article Immunology

Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients

Gururaj Rao Deshpande et al.

INDIAN JOURNAL OF MEDICAL RESEARCH (2020)

Add to Collection

Review Immunology

I mmunosenescence and Inflammaging: Risk Factors of Severe COVID-19 in Older People

Anna Julia Pietrobon et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Review Immunology

Immunological considerations for COVID-19 vaccine strategies

Mangalakumari Jeyanathan et al.

NATURE REVIEWS IMMUNOLOGY (2020)

Add to Collection

Article Immunology

Evaluation of cellular immunological responses in mono- and polymorphic clinical forms of post-kala-azar dermal leishmaniasis in India

H. Kaushal et al.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2016)

Add to Collection

© Peeref 2019-2024. All rights reserved.